Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1190-1197

  Twelves, C ^a   Scheithauer, W ^b   Mckendrick, J ^c   Seitz, J F ^d   Van Hazel, G ^e   Wong, A ^f   Diaz Rubio E ^g   Gilberg, F ^h   Cassidy, J ⁱ  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BOX HILL HOSPITAL   (Australia)

^d TIMONE HOSPITAL   (France)

^e Perth Oncology   (Australia)

^f TOM BAKER CANCER CENTRE   (Canada)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

5 fluorouracil folinic acid; Adjuvant therapy; Capecitabine; Colon cancer; Elderly; Pharmacodynamic markers

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 84860452474     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr366     Document Type: Article

References (25)

1. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358.
2. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-1887.
3. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939-944.
4. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250.
5. Haller DG, Catalano PJ, Macdonald JS et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671-8678.
6. Wolmark N, Bryant J, Smith R et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998; 90: 1810-1816.
7. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553-3559.
8. André T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896-2903.
9. André T, Quinaux E, Louvet C et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732-3738.
10. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
11. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
12. McCleary NAJ, Meyerhardt J, Green E et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol 2009; 27: 15s (Abstr 4010).
13. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575.
14. Taguchi T, Nakayama T, Masuda N et al. Low-dose capecitabine (X) monotherapy as first-line chemotherapy (CT) for metastatic breast cancer (MBC) KBCSG 0408. Proc Am Soc Clin Oncol 2008 (Abstr 193).
15. Sargent DJ, Patiyil S, Yothers G et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 25: 4569-4574.
16. Burris H, Diaz Rubio E, Douillard JY et al. Capecitabine (Xeloda®) versus i.v. bolus 5-FU/LV as adjuvant therapy for colon cancer (the X-ACT study): safety and efficacy maintained in the elderly. Presented at Advancing Cancer Care in the Elderly: Quality Care for Colorectal Cancer (ACCE 2004). Washington, DC, September 9-12, 2004.
17. Poplin EA, Benedetti JK, Estes NC et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23: 1819-1825.
18. Chau I, Norman AR, Cunningham D et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-557.
19. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
20. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
21. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
22. Veronese ML, Algazy K, Bearn L et al. Gefitinib in patients with advanced nonsmall cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania. Cancer Invest 2005; 23: 296-302.
23. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
24. Caronia D, Martin M, Sastre J et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 2011; 17: 2006-2013.
25. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26: 2118-2123.